• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Nu Skin Enterprises Inc.

    9/3/25 2:56:58 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care
    Get the next $NUS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001873048
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    NU SKIN ENTERPRISES, INC.
    SEC File Number
    001-12421
    Address of Issuer
    75 WEST CENTER ST
    ATTN: GREGORY BELLISTON
    PROVO
    UTAH
    84601
    Phone
    801-345-1000
    Name of Person for Whose Account the Securities are To Be Sold
    Clark Chayce David
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Class A
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    20000239433.564949771509/03/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Class A02/15/2022Restricted Stock VestingIssuerCheckbox not checked175602/15/2022Compensation
    Class A06/05/2022Restricted Stock VestingIssuerCheckbox not checked156406/05/2022Compensation
    Class A08/01/2022Restricted Stock VestingIssuerCheckbox not checked32908/01/2022Compensation
    Class A02/15/2023Restricted Stock VestingIssuerCheckbox not checked306102/15/2023Compensation
    Class A06/05/2023Restricted Stock VestingIssuerCheckbox not checked123406/05/2023Compensation
    Class A08/01/2023Restricted Stock VestingIssuerCheckbox not checked26008/01/2023Compensation
    Class A12/20/2023Restricted Stock VestingIssuerCheckbox not checked1154212/20/2023Compensation
    Class A02/15/2024Restricted Stock VestingIssuerCheckbox not checked25402/15/2024Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    09/03/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Chayce D. Clark

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $NUS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUS

    DatePrice TargetRatingAnalyst
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nu Skin Enterprises Reports Second Quarter Revenue at High End of Guidance and Earnings Per Share Above Guidance

    Company generates strong operating margin and cash position; narrows revenue and raises EPS guidance Nu Skin Enterprises Inc. (NYSE:NUS) today announced second quarter revenue at the high end of its guidance range and earnings per share exceeding guidance. Executive Summary Q2 2025 vs. Prior-year Quarter Revenue $386.1 million; (12.1)% 0.3% FX impact or $1.4 million Earnings Per Share (EPS) $0.43 compared to $(2.38) or $0.21 excluding impairment and other charges Customers 771,407; (14)% Paid Affiliates 130,799; (16)% Sales Leaders 29,593; (23)% "We are pleased with our solid performance in the second q

    8/7/25 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on Sept. 10, 2025, to shareholders of record on Aug. 29, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, w

    8/7/25 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises to Announce Second Quarter 2025 Financial Results

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced it will release second quarter 2025 results after the market closes on Thursday, Aug. 7. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, Aug. 21. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) fami

    7/10/25 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    SEC Filings

    View All

    SEC Form 144 filed by Nu Skin Enterprises Inc.

    144 - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    9/3/25 2:56:58 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    SEC Form 10-Q filed by Nu Skin Enterprises Inc.

    10-Q - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    8/7/25 6:24:37 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    8/7/25 4:33:03 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nu Skin downgraded by Jefferies with a new price target

    Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

    1/31/23 6:17:27 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    DA Davidson reiterated coverage on Nu Skin Enterprises with a new price target

    DA Davidson reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $50.00 from $47.00 previously

    2/17/22 4:46:52 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Citigroup reiterated coverage on Nu Skin Enterprises with a new price target

    Citigroup reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $49.00 from $43.00 previously

    11/24/21 11:03:39 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Woodbury Edwina D was granted 9 shares, increasing direct ownership by 0.02% to 42,969 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    9/11/25 6:27:03 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Director Nathanson Laura sold $79,296 worth of shares (6,489 units at $12.22), decreasing direct ownership by 16% to 33,149 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    9/4/25 5:12:26 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    EVP and General Counsel Clark Chayce David sold $239,400 worth of shares (20,000 units at $11.97), decreasing direct ownership by 8% to 233,140 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    9/4/25 5:10:10 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Hatchett Steven Keith bought $49,010 worth of shares (6,500 units at $7.54), increasing direct ownership by 4% to 162,065 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    5/28/25 6:26:44 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/12/24 4:47:17 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/6/24 10:20:59 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/4/24 10:21:31 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Financials

    Live finance-specific insights

    View All

    Nu Skin Enterprises Reports Second Quarter Revenue at High End of Guidance and Earnings Per Share Above Guidance

    Company generates strong operating margin and cash position; narrows revenue and raises EPS guidance Nu Skin Enterprises Inc. (NYSE:NUS) today announced second quarter revenue at the high end of its guidance range and earnings per share exceeding guidance. Executive Summary Q2 2025 vs. Prior-year Quarter Revenue $386.1 million; (12.1)% 0.3% FX impact or $1.4 million Earnings Per Share (EPS) $0.43 compared to $(2.38) or $0.21 excluding impairment and other charges Customers 771,407; (14)% Paid Affiliates 130,799; (16)% Sales Leaders 29,593; (23)% "We are pleased with our solid performance in the second q

    8/7/25 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on Sept. 10, 2025, to shareholders of record on Aug. 29, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, w

    8/7/25 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises to Announce Second Quarter 2025 Financial Results

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced it will release second quarter 2025 results after the market closes on Thursday, Aug. 7. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, Aug. 21. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) fami

    7/10/25 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Leadership Updates

    Live Leadership Updates

    View All

    Nu Skin Enterprises Appoints James Winett to Board of Directors

    Nu Skin Enterprises (US:NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company's board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. "Jim adds extensive expertise in strategic planning, operations and finance from his many years of consulting experience," said Steven J. Lund, executive chairman of the board. "He will also be an asset to our Rhyz businesses with his background in corporate transactions and advising small businesses and start-ups. We welcome Jim to the board and look forward to tapping into his insights and experience." Winett is a managing member of SIZE Adv

    6/2/25 12:19:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Appoints Mark A. Zorko to Board of Directors

    Nu Skin Enterprises (NYSE:NUS) today announced the appointment of Mark A. Zorko, a principal with executive management association Brentwood Advisory Group, to the company's board of directors. The board also appointed Zorko to serve on its audit committee and the nominating and corporate governance committee. "Mark brings extensive C-level leadership experience with several global public companies, as well as more than 20 years of board-level experience," said Steven J. Lund, executive chairman of the board. "We welcome Mark to the board and look forward to leveraging his extensive business insights and experience." Zorko is a principal with Brentwood Advisory, an association he co-found

    9/12/24 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care